Ignite Creation Date:
2024-05-06 @ 1:13 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03967938
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2020-07-09
First Post:
2019-02-11
Brief Title:
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Sponsor:
AZ-VUB
Organization:
AZ-VUB
Study Overview
Official Title:
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
1-2018 BSMO
Brief Summary:
At present targeted therapy with the PARP inhibitor olaparib has become standard of care in advanced platinum sensitive BRCA12 mutant ovarian cancer The key in this sensitivity is the loss of homologous recombination HR function The current project aims to treat patients with any type of cancer carrying in their germline a mutation in genes that generate such an homologous recombination deficiency HRD or have an acquired somatic mutation in their tumor with the targeted PARP inhibitor olaparib The project would thus bring access to a targeted drug matched to the genomic profile of the tumor of these patients and provide oncologists with information regarding efficacy and safety of olaparib in these patients This evidence could then later lead to a more routine regulatory access
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None